A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)
Status:
Completed
Trial end date:
2020-08-11
Target enrollment:
Participant gender:
Summary
This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of
imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single
intravenous (IV) dose of MK-7655A (a fixed ratio combination of
imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.